drugset
drugset / Trial / NCT04169932

The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma

NCT04169932 ↗

Phase 0 Unknown 20 enrolled Shanghai Longyao Biotechnology Inc., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a single arm, open-label study to evaluate the safety, tolerance and efficacy of CD20 CAR-T Cells in patients with relapsed and refractory B cell non-Hodgkin Lymphoma. Subjects receive a single intravenous infusion of CD20-CART cells per treatment course.

Timeline

Start
2019-11-22
Primary completion
2022-11-22
Completion
2022-11-22

Drugs

EvaluationDrugModalityDoseRoute
Subject CD19 CAR-T Cell therapy 1e+06 cells/kg Intravenous
Subject CD19 CAR-T Cell therapy 2e+06 cells/kg Intravenous
Subject CD19 CAR-T Cell therapy 4e+06 cells/kg Intravenous
Subject CD19 CAR-T Cell therapy 8e+06 cells/kg Intravenous

Indications

B-cell non-Hodgkin lymphoma